Showing 145–156 of 213 resultsSorted by latest
Pharma & Biotech
AbbVie also started the Phase 3 CERVINO trial to test ABBV-383 monotherapy in patients with relapsed or refractory multiple myeloma (MM) who have had at least two previous treatments.
Thermo Fisher expanded its clinical trial supply services by opening a new ultra-cold facility in Bleiswijk, Netherlands, to provide tailored support for high-value therapies like cell and gene therapies, biologics etc
Merck & Co Inc (MRK) Equity Report Q2FY24
MRK is focused on strategic business development to enhance its pipeline.
BSX also shared positive results from the ongoing MODULAR ATP clinical trial for the Modular CRM (mCRM ) System, which met all safety and effectiveness endpoints.
On July 2, 2024, Biogen (BIIB) acquired HI-Bio, a biotech company focused on treatments for severe immune diseases.
In Q2, NVS advanced its pipeline by completing FDA submissions for Scemblix in first-line CML and atrasentan in IgAN, and updating data for Kisqali in early breast cancer.
In May 2023, TEVA launched its “Pivot to Growth” strategy with four main goals: boosting key products, advancing innovation, strengthening its generics business, and optimizing operations.
Regeneron (REGN) is approaching 1mn patients using DUPIXENT worldwide.
Zoetis continues to advance animal care globally. Since its last earnings report, ZTS has received several new approvals.
In the second quarter, JNJ made significant progress across various areas.
Pfizer’s revenue is benefiting significantly from Seagen products.
In January 2023, Baxter planned to spin off its Kidney Care business into a separate company.